Is RTNXF or QYLD a better dividend investment in 2026?

RTNXF currently yields 2500.00% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: RTNXF offers higher current income.

What is the dividend yield difference between RTNXF and QYLD?

RTNXF has a forward dividend yield of 2500.00% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 2488.08 percentage points.

Home › Compare › RTNXF vs QYLD

RTNXF vs QYLD: Dividend Comparison 2026

RTNXF yields 2500.00% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RTNXF wins by $80609755877.34M in total portfolio value

INVESTMENT

TIME HORIZON10 years

RTNXF

● Live price

2500.00%

Share price

$0.08

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$80609755877.37M

Annual income

$74,729,580,081,858,750.00

Full RTNXF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — RTNXF vs QYLD

📍 RTNXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	RTNXF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, RTNXF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

RTNXF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RTNXF

Annual income on $10K today (after 15% tax)

$212,500.00/yr

After 10yr DRIP, annual income (after tax)

$63,520,143,069,579,940.00/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, RTNXF beats the other by $63,520,143,069,575,130.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RTNXF + QYLD for your $10,000?

RTNXF: 50%QYLD: 50%

100% QYLD50/50100% RTNXF

Portfolio after 10yr

$40304877938.70M

Annual income

$37,364,790,040,932,210.00/yr

Blended yield

92.71%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on RTNXF right now

RTNXF

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-22.6

Piotroski

4/9

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RTNXF buys

QYLD buys

Politician	Chamber	Ticker	Type	Amount	Date
Tim Moore	🏢 House	$QYLD	▼ Sell	$15,001 - $50,000	2025-05-02
Tim Moore	🏢 House	$QYLD	▲ Buy	$15,001 - $50,000	2025-04-07
Dwight Evans	🏢 House	$QYLD	▼ Sell	$1,001 - $15,000	2022-11-14
Dwight Evans	🏢 House	$QYLD	▼ Sell	$1,001 - $15,000	2020-10-29

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricRTNXFQYLD

Forward yield	2500.00% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$80609755877.37M ✓	$25.4K
Annual income after 10y	$74,729,580,081,858,750.00 ✓	$5,659.31
Total dividends collected	$80198875900.38M ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: RTNXF vs QYLD ($10,000, DRIP)

Year	RTNXF Portfolio	RTNXF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$260,700	$250,000.00	$10,352	$1,192.36	+$250.3K → RTNXF
2	$6,370,070	$6,091,121.50	$10,830	$1,347.57	+$6.36M → RTNXF
3	$145,912,632	$139,096,656.81	$11,460	$1,539.07	+$145.90M → RTNXF
4	$3,133,830,814	$2,977,704,297.75	$12,275	$1,777.84	+$3133.82M → RTNXF
5	$63,122,812,060	$59,769,613,088.96	$13,323	$2,078.95	+$63122.80M → RTNXF
6	$1,192,683,724,131	$1,125,142,315,226.76	$14,667	$2,463.34	+$1192683.71M → RTNXF
7	$21,144,559,711,004	$19,868,388,126,183.19	$16,396	$2,960.57	+$21144559.69M → RTNXF
8	$351,818,906,448,043	$329,194,227,557,269.44	$18,631	$3,612.97	+$351818906.43M → RTNXF
9	$5,495,491,397,671,320	$5,119,045,167,771,913.00	$21,548	$4,482.15	+$5495491397.65M → RTNXF
10	$80,609,755,877,367,070	$74,729,580,081,858,750.00	$25,398	$5,659.31	+$80609755877.34M → RTNXF

RTNXF vs QYLD: Complete Analysis 2026

RTNXF — Stock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Full RTNXF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this RTNXF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RTNXF vs SCHD RTNXF vs JEPI RTNXF vs O RTNXF vs KO RTNXF vs MAIN RTNXF vs XYLD RTNXF vs JEPQ RTNXF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.